A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors With and Without Brain Metastases
Interventions: DRUG: ANG1005
Sponsor: Angiochem Inc